{"id":"W2760650159","doi":"10.1016/j.urolonc.2017.09.004","title":"Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma","year":2017,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Sunitinib; Medicine; Renal cell carcinoma; Toxicity; Internal medicine; Oncology; Progression-free survival; Retrospective cohort study; Urology; Progressive disease; Dosing; Surgery; Overall survival; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001004617,0.000259643,0.001396011,0.0005784343,0.0003754662,0.0006292298,0.00036272,0.0003462822,0.002243662],"category_scores_gemma":[0.001238311,0.0001499888,0.000868577,0.0004047442,0.0002113356,0.0005130793,0.0002178714,0.001196218,0.0003353517],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001077047,"about_ca_system_score_gemma":0.0005389058,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007779759,"about_ca_topic_score_gemma":0.002763793,"domain_scores_codex":[0.9995995,0.0001066666,0.00004156812,0.00006447476,0.0000870452,0.0001007354],"domain_scores_gemma":[0.9996673,0.0001087657,0.00007881027,0.00003818903,0.00002981165,0.0000772063],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.04927913,0.005482383,0.02009058,0.0008998346,0.001225675,0.0005609783,0.0005133408,0.01325183,0.03407577,0.0008085208,0.005494791,0.8683172],"study_design_scores_gemma":[0.03345564,0.2613869,0.4933067,0.0004461879,0.002972728,0.005661055,0.0006141944,0.03358322,0.1055255,0.003579885,0.05919937,0.0002687227],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877814,0.006790294,0.0007555607,0.0004830152,0.0002057571,0.000184019,0.0001810838,0.0001696725,0.003449292],"genre_scores_gemma":[0.9971327,0.001041873,0.000422038,0.0001199294,0.00005269805,0.0000517571,0.0001488877,0.00002263517,0.001007542],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002243662,"threshold_uncertainty_score":0.007814527,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0449774807537125,"score_gpt":0.3366655952344272,"score_spread":0.2916881144807147,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}